Prochem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.95 Cr
as on 16-11-2024
- Satisfied Charges ₹ 2.18 M
as on 16-11-2024
- Revenue 1.86%
(FY 2023)
- Profit 105.02%
(FY 2023)
- Ebitda 90.32%
(FY 2023)
- Net Worth 40.09%
(FY 2023)
- Total Assets -4.84%
(FY 2023)
About Prochem Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹10.95 Cr. The company has closed loans amounting to ₹2.18 M, as per Ministry of Corporate Affairs (MCA) records.
Mahesh Badlani and Sandeep Bhargava serve as directors at the Company.
- CIN/LLPIN
U36999UR2016PTC007288
- Company No.
007288
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Sep 2016
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Prochem Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Badlani  | Director | 01-Sep-2016 | Current |
| Sandeep Bhargava | Director | 04-Jun-2021 | Current |
Financial Performance of Prochem Pharmaceuticals.
Prochem Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.86% increase. The company also saw a substantial improvement in profitability, with a 105.02% increase in profit. The company's net worth Soared by an impressive increase of 40.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prochem Pharmaceuticals?
In 2023, Prochem Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 09 Jun 2023 | ₹10.00 Cr | Open |
Axis Bank Limited Creation Date: 27 Feb 2020 | ₹9.50 M | Open |
Others Creation Date: 27 Jul 2022 | ₹2.18 M | Satisfied |
How Many Employees Work at Prochem Pharmaceuticals?
Prochem Pharmaceuticals has a workforce of 309 employees as of Sep 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prochem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prochem Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
